Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
REVEAL: Response to Velcade combination chemotherapy in AL amyloidosis
2009-014906-33Phase 2Terminated
- Sponsor
- University College London
- Start
- Jun 2010
- Modality
- Reversible Covalent Inhibitors → Covalent Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2 trial of bortezomib in light-chain amyloidosis, amyloidosis and paraproteinemia (2 arms), sponsored by University College London. Primary endpoint: Clonal response of the underlying plasma cell dyscrasia to VD and to CVD. Started Jun 2010; status: terminated.
02
Drugs
bortezomib
03
Conditions
light-chain amyloidosisamyloidosisparaproteinemia
Beyond the preview
Go deeper on 2009-014906-33.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2009-014906-33.